Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) Assets Average: 2011-2025

Historic Assets Average for Ligand Pharmaceuticals (LGND) over the last 13 years, with Sep 2025 value amounting to $1.2 billion.

  • Ligand Pharmaceuticals' Assets Average rose 33.17% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 33.17%. This contributed to the annual value of $864.5 million for FY2024, which is 11.56% up from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' Assets Average stood at $1.2 billion, which was up 30.82% from $927.0 million recorded in Q2 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Assets Average peaked at $1.3 billion during Q1 2021, and registered a low of $763.7 million during Q3 2023.
  • Its 3-year average for Assets Average is $888.8 million, with a median of $890.1 million in 2024.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Assets Average crashed by 34.50% in 2023, and later skyrocketed by 33.17% in 2025.
  • Quarterly analysis of 5 years shows Ligand Pharmaceuticals' Assets Average stood at $1.3 billion in 2021, then fell by 29.48% to $906.6 million in 2022, then fell by 14.16% to $778.2 million in 2023, then increased by 21.86% to $948.3 million in 2024, then spiked by 33.17% to $1.2 billion in 2025.
  • Its last three reported values are $1.2 billion in Q3 2025, $927.0 million for Q2 2025, and $923.6 million during Q1 2025.